The experimental 5-HT1A receptor agonist and D2 receptor antagonist was not effective on primary or secondary endpoints
News
Sanofi/Regeneron’s Libtayo shows benefit in BCC
BCC marks the second non-melanoma skin cancer for which Libtayo has demonstrated first-in-class data, the firms note
JEDI launches billion molecules agains COVID19 challenge
The Billion Molecules against Covid19 Grand Challenge aims to screen billions of molecules with blocking interactions on SARS-CoV-2
Crescendo links with CRUK to progress cancer therapy
The charity’s Centre for Drug Development will sponsor and fund a future Phase I clinical trial for CB213
Gov’t begins roll out of track and trace COVID-19 app
The programme is expected to roll out nationally mid-May
Inaugural Patient Partnership Index 2020 launches
The Index is a first-of-its-kind opportunity for pharma companies to showcase, benchmark and measure the quality of their partnership working with patient communities
NICE publishes latest set of COVID-19 guidelines
The first concerns the care of immunocompromised children and young people and the second antibiotics for pneumonia in hospitalised adults
EU approves label update for AZ’ Lokelma
Update provides dosing regimen specifically for hyperkalaemia in patients with end-stage renal disease on stable haemodialysis
LifeArc, MRC create £16m fund to set up gene therapy hubs
The hubs aim to address challenges faced by academics as they seek to advance novel gene therapy research into early stage clinical trials
EU leaders pledge support for global COVID-19 effort
The new initiate strives to raise 7.5 billion euros to aid the discovery and development of a coronavirus vaccine
FDA issues ’emergency use’ green light for Gilead’s remdesivir
The move follows data from a clinical trial showing that the drug accelerated recovery time in hospitalised patients
Manchester Uni researchers develop domestic COVID-19 test
The prototype test is based on the fact that sugars coat all human cells
Vicore Pharma bags MHRA nod for COVD-19 trial in record time
ATTRACT (Angiotensin II Type Two Receptor Agonist Covid-19 Trial) is targeting hospitalised patients treated with basic respiratory care, but not mechanical ventilation
NICE joins international COVID-19 pandemic response
NICE is sharing its work with initiatives such as the WHO’s Evidence Collaborative for COVID-19
CHMP begins rolling review of Gilead’s remdesivir
It is expected that the move will allow the EMA to complete its assessment of the drug significantly earlier than with a regular evaluation procedure
